OTCMKTS:ASNB EKIMAS (ASNB) Stock Price, News & Analysis $3.74 -0.01 (-0.27%) As of 06/15/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About EKIMAS Stock (OTCMKTS:ASNB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get EKIMAS alerts:Sign Up Key Stats Today's Range$3.45▼$3.7450-Day Range$2.21▼$4.1052-Week Range$0.55▼$1.75Volume830 shsAverage Volume3,162 shsMarket Capitalization$21.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview EKIMAS Corp. engages in the development of polymer materials, which provide characteristics in the design and development of medical devices. Its biomaterials are used in devices that are designed for treating a range of anatomical sites and disease states. The firm's products include ChronoFlex, ChronoSil, HydroMed, HydroThane, and PolyBlend. The company was founded in 1993 and is headquartered in Las Vegas, NV. Read More Receive ASNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EKIMAS and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASNB Stock News HeadlinesEKIMAS CORPORATION COMPLETES THE EXERCISE OF WARRANTSMarch 8, 2023 | finance.yahoo.comNORDICUS PARTNERS A/S COMPLETES REVERSE ACQUISITION TRANSACTION WITH EKIMAS CORPORTIONMarch 1, 2023 | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.June 16 at 1:00 AM | Porter & Company (Ad)ASNB.PK - Ekimas Corp | Stock Price & Latest News | ReutersSeptember 14, 2022 | reuters.comUpdated EKIMAS Corporation Announces Special Cash DistributionSeptember 12, 2022 | finance.yahoo.comWhat does ‘WYLL’ mean on TikTok and Snapchat?September 10, 2022 | yahoo.comEKIMAS Corporation (ASNB)August 28, 2022 | finance.yahoo.comSee More Headlines ASNB Stock Analysis - Frequently Asked Questions How have ASNB shares performed this year? EKIMAS's stock was trading at $5.00 on January 1st, 2026. Since then, ASNB shares have decreased by 25.2% and is now trading at $3.74. How were EKIMAS's earnings last quarter? EKIMAS Co. (OTCMKTS:ASNB) released its quarterly earnings data on Thursday, October, 16th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.29 by $0.02. How do I buy shares of EKIMAS? Shares of ASNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of EKIMAS own? Based on aggregate information from My MarketBeat watchlists, some other companies that EKIMAS investors own include Associated Banc (ASB), MediWound (MDWD), PermRock Royalty Trust (PRT), Meta Platforms (META), Adobe (ADBE), Actinium Pharmaceuticals (ATNM) and CytoDyn (CYDY). Company Calendar Last Earnings10/16/2014Today6/16/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryBusiness Services Current SymbolOTCMKTS:ASNB Previous SymbolAMEX:ASB CIK1011060 Webwww.advbiomaterials.com Phone(424) 256-8560Fax978-657-0074Employees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$290 thousand Net MarginsN/A Pretax MarginN/A Return on Equity-7,902.31% Return on Assets-5,274.01% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book124.67Miscellaneous Outstanding Shares5,799,000Free Float5,347,000Market Cap$21.69 million OptionableNot Optionable Beta0.37 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:ASNB) was last updated on 6/16/2026 by MarketBeat.com Staff. From Our PartnersThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredBUY THIS: Claim a backdoor stake in SpaceXThere may be a way to claim pre-IPO exposure to SpaceX before it ever hits public markets - using a simple tra...Chaikin Analytics | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredBuy now or wait?SpaceX may be the biggest IPO in history, but according to Joel Litman - who called AMD before it rose as much...Altimetry | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredWhat to Own for America’s Real-Economy ResetWhile the S&P 500 gained 13.5% last year, gold ran roughly 60% - and one overlooked gold-linked asset soared a...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EKIMAS Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share EKIMAS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
